- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| FREENOME Aktie jetzt für 0€ handeln | |||||
| 30.09. | Abbott rolls out SimpleScreen colorectal cancer blood test developed by Freenome | 5 | MassDevice | ||
| 23.09. | Freenome, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 18.08. | Freenome, Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 18.08. | Freenome stock initiated at Buy by TD Cowen on liquid biopsy tech | 1 | Investing.com | ||
| 17.08. | BTIG startet Freenome mit Kaufempfehlung und sieht fast 50 % Kurspotenzial | 1 | Investing.com Deutsch | ||
| 17.08. | BTIG initiates Freenome stock with buy rating on cancer test potential | 1 | Investing.com | ||
| 17.08. | Jefferies initiates Freenome stock with buy rating on cancer screening potential | 2 | Investing.com | ||
| 17.08. | Jefferies startet Freenome mit Kaufempfehlung: Hohes Potenzial bei Krebs-Screening | 1 | Investing.com Deutsch | ||
| 14.08. | Freenome GAAP EPS of -$2.59 | 1 | Seeking Alpha | ||
| 12.08. | Freenome, Inc.: FDA Grants Breakthrough Device Designation to Freenome's Blood-Based SimpleScreen Lung Cancer Screening Test | 278 | GlobeNewswire (Europe) | BRISBANE, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Freenome, Inc. (Nasdaq: FRNM), an early cancer detection company developing blood-based screening tests, today announced that the U.S. Food and... ► Artikel lesen | |
| 24.07. | Freenome, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 20.07. | NSE - Freenome, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | 2 | SEC Filings | ||
| 20.07. | Freenome Holdings, Inc. - 15-15D, Suspension of duty to report | 2 | SEC Filings | ||
| 20.07. | Freenome, Inc. - 8-A12B, Registration of securities | 1 | SEC Filings | ||
| 20.07. | Krebsdiagnostik-Spezialist Freenome geht via SPAC an die Nasdaq | - | Investing.com Deutsch | ||
| 20.07. | Freenome, Inc.: Freenome Debuts as a Publicly Traded Company Focused on Blood-Based Early Cancer Detection | 478 | GlobeNewswire (Europe) | - Freenome common stock expected to begin trading on the Nasdaq Capital Market under the ticker symbol "FRNM" on July 21, 2026 - - Gross proceeds to Freenome totaled more than $300 million through... ► Artikel lesen | |
| 13.07. | Freenome colorectal cancer test data improve on earlier results | 1 | BioPharma Dive | ||
| 11.06. | Freenome Holdings, Inc. - S-4/A, Registration of securities, business combinations | - | SEC Filings | ||
| 01.06. | Freenome Holdings, Inc. - S-4/A, Registration of securities, business combinations | 2 | SEC Filings | ||
| 28.04. | Freenome Holdings, Inc. - S-4, Registration of securities, business combinations | - | SEC Filings |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 259,86 | 0,00 % | Praxis Precision Medicine Q2 2026 Earnings Call Transcript | ||
| ERASCA | 16,030 | 0,00 % | Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial Results | Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,590 | 0,00 % | Summit Therapeutics Secures $2B Strategic Investment From AstraZeneca | LONDON (dpa-AFX) - Summit Therapeutics Inc. (SMMT) on Monday announced the closing of AstraZeneca's (AZN) $2 billion strategic equity investment, which will support accelerated development of... ► Artikel lesen | |
| QIAGEN | 40,190 | +1,55 % | Pharma-Aktien starten durch: Merck, Qiagen und Bayer im Höhenflug - KI-Boom und US-Megadeal befeuern Branche | Die Aktien von Pharma- und Biotech-Unternehmen erleben am Dienstag einen starken Aufwärtstrend, angeführt von Merck KGaA. Investoren setzen auf Übernahmespekulationen und den KI-getriebenen Innovationsschub... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,360 | 0,00 % | 90% der Wirkstoffkandidaten scheitern: Wie Nvidia, Bristol Myers Squibb, Recursion und NeuroThera das größte Pharmaproblem angreifen | ||
| KINIKSA PHARMACEUTICALS | 79,78 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $980 - $995 million -- KPL-387... ► Artikel lesen | |
| MODERNA | 200,50 | -0,17 % | Moderna-Aktie: Steht der Ausbruch bevor? | Die Moderna-Aktie setzt ihre spektakuläre Erholung fort und notiert bei 190,01 US$. Damit hat der Kurs der Moderna-Aktie eine mehrjährige Widerstandszone überwunden. Der Ausbruch eröffnet technisch... ► Artikel lesen | |
| NURIX THERAPEUTICS | 22,350 | 0,00 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia | First patient enrolled in cohort combining bexobrutideg with venetoclax Initial cohort to focus on relapsed/refractory CLL, with potential expansion to first-line CLL Strategy includes evaluation... ► Artikel lesen | |
| ADMA BIOLOGICS | 10,360 | 0,00 % | Kehoe Law Firm, P.C.: ADMA Biologics (ADMA) Shareholder Alert: Kehoe Law Firm Investigates Potential Fiduciary Duty Breaches | Philadelphia, Pennsylvania--(Newsfile Corp. - August 5, 2026) - Kehoe Law Firm, P.C. is investigating whether certain officers and directors of ADMA Biologics, Inc. ("ADMA," "ADMA Biologics," or... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 112,45 | 0,00 % | Kymera Therapeutics: Raymond James startet Coverage mit "Outperform"-Rating | ||
| TANGO THERAPEUTICS | 23,820 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| IMMUNOVANT | 30,470 | 0,00 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen | |
| DYNE THERAPEUTICS | 16,645 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) | - Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion of ACHIEVE showed functional improvement versus baseline, versus placebo and versus... ► Artikel lesen | |
| COGENT BIOSCIENCES | 31,020 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSM PDUFA target action date set... ► Artikel lesen | |
| ABSCI | 10,165 | +0,05 % | Absci Corporation: Absci Announces Preliminary Details for Phase 2 STORYLINE Trial of AI-Designed Antibody ABS-201 for Endometriosis | Phase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) Anticipated initiation of Phase 2 trial... ► Artikel lesen |
Das Unternehmen FREENOME INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,030 (-0,19 %) liegt der Kurs bei 15,750 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FREENOME INC finden Sie auf Wallstreet Online.